Keytruda (pembrolizumab; Merck & Co) is a humanized monoclonal antibody designed to inhibit the PD-1 co-inhibitory receptor. The interaction between PD-1 and its primary ligand, PD-L1, inhibits T-cell proliferation and survival, and induces apoptosis of tumor-specific T-cells. The disruption of this interaction reduces the ability of the tumor to evade immune system targeting and enhances antitumor immune responses. It has also been hypothesized that blocking the PD-1/PD-L1 interaction may preferentially release the cytotoxic function of tumor-specific T cells with fewer toxic effects than those seen with other immune checkpoint inhibitors.
Keytruda (pembrolizumab; Merck & Co) is the first programmed death-1 (PD-1) receptor-targeted therapy to enter the diffuse large Bcell lymphoma (DLBCL) market after the US Food and Drug Administration (FDA) granted it accelerated conditional approval in June 2018, based on the Phase II KEYNOTE-170 and the Phase Ib KEYNOTE-013 trials.
However, Keytruda's market potential in this indication remains limited due to its approval for primary mediastinal B-cell lymphoma (PMBCL), which only accounts for a small percentage of non-Hodgkin's lymphoma (NHL) patients. To potentially expand Keytruda's market size, Merck is investigating its safety and tolerability in combination with cluster of differentiation 19 (CD19) bispecific T-cell engager (BiTE) Blincyto (blinatumomab; Amgen/AstraZeneca/Astellas) in a Phase Ib/III clinical trial. However, this combination remains in early-phase development and is not expected to be approved for use in DLBCL over the next decade.
Key Topics Covered:
- Drug Overview
- Product Profiles
- Keytruda : NHL: Diffuse large B-cell lymphoma (DLBCL)
- Keytruda : Non-small cell lung cancer (NSCLC)
- Keytruda : Melanoma
- Keytruda : Gastric cancer
- Keytruda : Colorectal cancer (CRC)
- Keytruda : Head and neck cancer
- Keytruda : Hepatocellular carcinoma (HCC)
- Keytruda : Bladder cancer
- Keytruda : Renal cell cancer (RCC)
- Keytruda : Breast cancer: triple-negative
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/4t1box